Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementBlue Cross MA Immersive VR Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 245

    Immersive Virtual Reality Therapy for Chronic Lower Back Pain

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 245 alerts

    Get alerted when Policy 245 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of FDA-authorized prescription virtual reality digital therapeutics using dedicated immersive hardware and software to treat chronic lower back pain for Commercial and Medicare Blue members. The service is considered investigational and is not covered under this policy.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyImmersive Virtual Reality Therapy for Chronic Lower Back Pain
    Policy CodePolicy 245
    Change TypeNew policy
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionObtain precertification or preauthorization when a service described in this policy is performed inpatient.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy was created stating that FDA-authorized prescription virtual reality digital therapeutics for chronic lower back pain are investigational.

    A new medical policy was created stating that FDA-authorized prescription virtual reality digital therapeutics for chronic lower back pain are investigational.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    InvestigationalCoverage status
    3Required scope elements
    0770TInvestigational code identified
    N=1,067Largest supporting trial

    Coverage Criteria

    Products within policy scope

    A product is within the scope of this review only when ALL of the following are met.

    Required scope elements

    • PDT: The software performs one or more medical purposes as the primary therapeutic component of an integrated hardware-software system and is not used solely to store or transmit medical information.
    • FDA authorization: The product has received marketing clearance or approval by the U.S. Food and Drug Administration (FDA).
    • Prescription: The product is prescribed by a healthcare provider.

    Technology evaluation criteria

    The technology must satisfy ALL of the following evaluation criteria.

    • Regulatory approval: The technology has final approval from the appropriate governmental regulatory bodies.
    • Evidence quality: Scientific evidence permits conclusions concerning the effect of the technology on health outcomes.
    • Net health outcome: The technology improves the net health outcome.

      The technology must assure protection of sensitive patient health information as required by HIPAA.

    • Established alternatives: The technology is as beneficial as any established alternatives.
    • Real-world attainability: The improvement is attainable outside investigational settings.

    FDA-authorized prescription virtual reality digital therapeutics for chronic lower back pain are considered investigational and are excluded from coverage.

    The policy determines that FDA-authorized prescription virtual reality digital therapeutics for chronic lower back pain are investigational. This determination is effective October 1, 2026.

    The evidence is insufficient to determine that RelieVRx, skills-based VR, or Virtual Reality Neuroscience-based Therapy (VRNT) improves net health outcomes for individuals with chronic lower back pain. Limitations include inconsistent findings, lack of clinically meaningful effects in some comparisons, small or nonblinded studies, limited generalizability, and limited follow-up.

    Investigational Coding

    Investigational CPT CodesCPTExperimental
    0770TVirtual reality technology to assist therapy (List separately in addition to code for primary procedure)

    Provider and Billing Actions

    Prior Authorization

    Inpatient Authorization Required

    Precertification/preauthorization is required for all products when a service described in this policy is performed in the inpatient setting.

    • Applies to Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM members.
    Denial Risk

    Outpatient Service Not Covered

    Services described in this policy are not covered when performed outpatient for the affected member products listed below.

    • Commercial Managed Care (HMO and POS)
    • Commercial PPO and Indemnity
    • Medicare HMO Blue SM
    • Medicare PPO Blue SM

    Policy Background

    This policy evaluates prescription digital therapeutics that deliver their primary therapeutic effect through immersive virtual reality hardware and software for the treatment of chronic lower back pain. The review considers whether the available evidence demonstrates improvement in net health outcomes, including evidence for RelieVRx, skills-based VR, and Virtual Reality Neuroscience-based Therapy.

    Key Definitions

    Prescription digital therapeutic (PDT)
    TermPrescription digital therapeutic (PDT)
    Primary functionSoftware that performs one or more medical purposes as the primary therapeutic component of a hardware-software system.
    ExclusionSoftware used solely to store or transmit medical information is excluded from this definition.
    Immersive virtual reality therapeutic
    TermImmersive virtual reality therapeutic
    Therapeutic deliveryA prescription digital therapeutic that delivers its primary therapeutic intervention through integrated hardware and software using immersive visual stimulation.

    Not Covered Services

    Prescription immersive virtual reality digital therapeutics for chronic lower back pain are considered investigational and are not covered. This includes FDA-authorized prescription virtual reality digital therapeutics used for this indication.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyImmersive Virtual Reality Therapy for Chronic Lower Back Pain
    Policy CodePolicy 245
    Change TypeNew policy
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionObtain precertification or preauthorization when a service described in this policy is performed inpatient.
    SourceLink
    On This Page
    Coverage CriteriaInvestigational CodingProvider and Billing ActionsPolicy BackgroundKey DefinitionsNot Covered Services

    The technology must demonstrate usability in a real-world setting.

    Documentation Required

    Scope Documentation Required

    Document that the product and prescription satisfy the policy scope requirements for a prescription digital therapeutic addressing chronic lower back pain.

    • The product is a prescription digital therapeutic (PDT) in which software performs one or more medical purposes as the primary therapeutic component of a hardware-software system; software used solely to store or transmit medical information does not qualify.
    • The product has received U.S. Food and Drug Administration (FDA) marketing clearance or approval, including De Novo classification or 510(k) clearance where applicable.
    • The product is prescribed by a healthcare provider.
    • The therapeutic intervention is delivered through an immersive virtual reality headset and dedicated hardware-software system.
    Denial Risk

    Investigational Service

    The use of FDA-authorized prescription virtual reality digital therapeutics for chronic lower back pain is considered investigational and is not covered for the member products addressed by this policy.

    • Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM members.
    Documentation Required

    Product or Prescription Outside Scope

    A product or prescription is outside the policy scope when it does not meet all required characteristics for the reviewed prescription immersive virtual reality therapeutic.

    • The product is not a prescription digital therapeutic in which software is the primary therapeutic component of an integrated hardware-software system.
    • The software is used solely to store or transmit medical information.
    • The product lacks FDA marketing clearance or approval, including applicable De Novo classification or 510(k) clearance.
    • The product is not prescribed by a healthcare provider.
    • The product does not use dedicated immersive virtual reality hardware, such as a VR headset, to deliver the primary therapeutic intervention for chronic lower back pain.
    Billing Rule

    Investigational CPT Code

    CPT 0770T is considered investigational for the member products addressed by this policy. Reporting the code does not establish coverage or provider reimbursement; member contract benefits determine individual coverage or non-coverage.

    • CPT 0770T — Virtual reality technology to assist therapy (list separately in addition to code for primary procedure).
    • Use the most up-to-date industry-standard procedure, revenue, diagnosis, and applicable modifier codes.
    Denial Risk

    Investigational Use May Be Denied

    Claims for use of FDA-authorized prescription virtual reality digital therapeutics for chronic lower back pain may be denied because the policy classifies this use as investigational and not covered.

    • Effective October 1, 2026, the use described above is considered investigational.
    • Coverage is subject to the member's contract benefits in effect at the time of service.
    Hardware context
    The product typically requires dedicated hardware, including a virtual reality headset, through which proprietary software delivers the primary therapeutic intervention.
    Policy-scope indication
    IndicationManagement of chronic lower back pain.
    Technology requirementUse of a prescription virtual reality therapeutic that has received marketing clearance or approval from the U.S. Food and Drug Administration (FDA).
    Prescribing requirementThe therapeutic must be prescribed by a healthcare provider.
    Virtual Reality Neuroscience-based Therapy (VRNT)
    TermVirtual Reality Neuroscience-based Therapy (VRNT)
    Type of therapyA prescription virtual reality digital therapeutic.
    Population and useEvaluated for individuals with chronic lower back pain.
    Regulatory statusReceived FDA 510(k) clearance in October 2023.